• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research

Clinical characteristics, multiorgan dysfunction and outcomes of patients with COVID-19: a prospective case series
This study provides further evidence that COVID-19 is a multisystem disease involving neurologic, cardiac and thrombotic dysfunction, without evidence of hepatic dysfunction. Patients have persistent organ dysfunction after hospital discharge, underscoring the need for research on long-term outcomes of COVID-19 survivors.PMID:35853662 | DOI:10.9778/cmajo.20210151
Source: cmaj - July 19, 2022 Category: General Medicine Authors: Kimia Honarmand Kyle Fiorini Debarati Chakraborty Daniel Gillett Karishma Desai Claudio Martin Karen J Bosma Marat Slessarev Ian M Ball Tina Mele Danielle LeBlanc Sameer Elsayed Alejandro Lazo-Langner Mike J Nicholson Robert Arntfield John Basmaji Source Type: research

Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study
Conclusions Our estimated background rates help contextualise observed events of these potential adverse events of special interest and to detect potential safety signals related to COVID-19 vaccines.
Source: BMJ Open - December 17, 2021 Category: General Medicine Authors: Nasreen, S., Calzavara, A. J., Sundaram, M. E., MacDonald, S. E., Righolt, C. H., Pai, M., Field, T. S., Zhou, L. W., Wilson, S. E., Kwong, J. C. Tags: Open access, Public health, COVID-19 Source Type: research

COVID-19 and the Cardiovascular System: Insights into Effects and Treatments
Can J Physiol Pharmacol. 2021 Sep 21. doi: 10.1139/cjpp-2021-0093. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19), an acute and highly transmissible infectious disease has reached a pandemic level since March 11, 2020 and continues to challenge the healthcare system worldwide. The pathogenesis of COVID-19 is a complex process involving mechanisms that suppress the host antiviral and innate immune response, while triggering marked activation of coagulation and hyperinflammation leading to cytokine storm in severe COVID-19. This review summarizes current evidence related to COVID-19-associated cardiovascul...
Source: Canadian Journal of Physiology and Pharmacology - September 21, 2021 Category: Drugs & Pharmacology Authors: Joey-Bahige Chammas Dylan Delaney Naim Chabaytah Sarah Abdulkarim Adel Schwertani Source Type: research

From cellular function to global impact: the vascular perspective on COVID-19
Can J Surg. 2021 May 12;64(3):E289-E297. doi: 10.1503/cjs.023820.ABSTRACTSince COVID-19 was declared a pandemic a year ago, our understanding of its effects on the vascular system has slowly evolved. At the cellular level, SARS-CoV-2 - the virus that causes COVID-19 - accesses the vascular endothelium through the angiotensin-converting enzyme 2 (ACE-2) receptor and induces proinflammatory and prothrombotic responses. At the clinical level, these pathways lead to thromboembolic events that affect the pulmonary, extracranial, mesenteric, and lower extremity vessels. At the population level, the presence of vascular risk fact...
Source: Canadian Journal of Surgery - May 12, 2021 Category: Surgery Authors: Shira A Strauss Chanhee Seo Marc Carrier Prasad Jetty Source Type: research

Pages: 1  2